Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.51 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | RB1 | P06400 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473259 | 0.83 | RB1 (0.61) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL14361488 | 0.79 | CDC42 (0.61) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL14361495 | 0.79 | BRD3 (0.57) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL14361410 | 0.77 | RB1 (0.69) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL22135938 | 0.74 | CYP2D6 (0.58) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL22135878 | 0.74 | CYP2D6 (0.58) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL22135735 | 0.73 | CDC42 (0.54) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL22135738 | 0.73 | CDC42 (0.54) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL4152508 | 0.72 | GAA (0.78) | GAACASP6PRMT5CDC42BRD3 | |
| SCHEMBL5456595 | 0.71 | RB1 (0.56) | GAACASP6PRMT5CDC42BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| EP-1678137-A1 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | CHIRON CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037791-A1 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | GAA 1417/4885CASP6 3264/4885PRMT5 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.